Please use this identifier to cite or link to this item:
Title: Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.
Austin Authors: Sasadeusz, Joe;Grigg, Andrew P ;Hughes, Peter D;Lee Lim, Seng;Lucas, Michaela;McColl, Geoff;McLachlan, Sue Anne;Peters, Marion G;Shackel, Nicholas;Slavin, Monica;Sundararajan, Vijaya;Thompson, Alexander;Doyle, Joseph;Rickard, James;De Cruz, Peter;Gish, Robert G;Visvanathan, Kumar
Affiliation: University of Queensland Oral Health Centre, 288 Herston Road, Queensland 4006, Australia
University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia
Burnet Institute, 85 Commercial Road, Melbourne, Victoria 3004, Australia
The Alfred and Monash University, 85 Commercial Road, Melbourne, Victoria 3004, Australia
Department of Public Health, La Trobe University, Plenty Road, Bundoora, Victoria 3086, Australia
Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia
St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia
University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia
Ingham Institute, 1 Campbell Street, Liverpool, Sydney, North South Wales 2170, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Peter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Victoria 3000, Australia
Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia
National University of Singapore, 21 Lower Kent Ridge Road, Singapore 119077, Singapore
University of California, San Francisco, S357 Parnassus Avenue, San Francisco, CA 94143, USA
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
Austin Health, Heidelberg, Victoria, Australia
Issue Date: Aug-2019
Date: 2019-06-05
Publication information: Clinics in liver disease 2019; 23(3): 521-534
Abstract: Because of the relatively high prevalence of both hepatitis B infection and various forms of autoimmune inflammatory diseases treated with aggressive immunotherapy, reactivation of hepatitis B occurs in a substantial number of patients. The risk of reactivation depends on the degree and duration of immunosuppression. A large number of drug treatments have resulted in reactivation of hepatitis B virus infection and, based on the mechanisms and extent of immunosuppression, recommendations for some of the newer classes of immunosuppressive drugs are provided.
DOI: 10.1016/j.cld.2019.04.012
Journal: Clinics in liver disease
PubMed URL: 31266625
Type: Journal Article
Subjects: Anti-CD20
Direct-acting antivirals
Hepatitis B
Inflammatory bowel diseases
Rheumatoid arthritis
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 12, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.